Factory 99% Efinaconazole Powder CAS 164650-44-6 Chemical Intermediate Efinaconazole

• Customization: Available
• Powder: Yes
• Customized: Customized
• Model NO.: A931
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Children, Adult
• State: Powder
• Purity: >99%
• Name: Efinaconazole
• CAS: 164650-44-6
• Appearance: White Powder
• Assay: 99%
• OEM: Available
• Sample: Available
• Suitable: Adult
• MOQ: 1g
• Function: Chemical Intermediate
• Transport Package: Foil Bag
• Specification: 99
• Trademark: /
• Origin: China
• Production Capacity: 10000 Kgs Per Month

Product Description

 

Product Name	Efinaconazole
Appearance	White Powder
CAS NO.	164650-44-6
Storage	Keep in a cool, dry, dark location

 

Efinaconazole is a synthetic triazole antifungal agent with a chemical formula of C18H22F2N4O. It is a white to off-white crystalline powder that is insoluble in water but soluble in organic solvents.

 

1. Topical Treatment of Onychomycosis: Efinaconazole is primarily applied topically to treat toenail fungal infections (onychomycosis). It is formulated as a nail lacquer solution for easy application to the affected nails.
2. Dermatological Use: Although less common, efinaconazole may also have potential applications in the treatment of other dermatological fungal infections under specific circumstances.

1. Antifungal Activity: Efinaconazole exhibits broad-spectrum antifungal activity against dermatophytes, the primary cause of onychomycosis. It works by inhibiting the fungal cytochrome P450 14α-demethylase enzyme, which disrupts ergosterol synthesis and leads to fungal cell membrane disruption and cell death.
2. Long-Lasting Effect: When applied topically as a nail lacquer, efinaconazole penetrates deep into the nail plate and maintains therapeutic concentrations for an extended period, facilitating effective treatment of onychomycosis.
3. Improved Patient Compliance: The topical formulation of efinaconazole eliminates the need for oral medication, which can improve patient compliance and reduce the risk of systemic side effects associated with oral antifungals.